NasdaqCM:VRDNBiotechs
Viridian Therapeutics (VRDN): Evaluating Valuation After FDA Filing and Breakout Earnings Performance
Viridian Therapeutics (VRDN) delivered a double dose of news that is catching investors’ attention. The company posted a dramatic jump in third quarter revenue and a much smaller net loss, while also submitting its BLA for veligrotug to the FDA.
See our latest analysis for Viridian Therapeutics.
Viridian Therapeutics has been shaping up as one of the year’s standout movers, with its share price up 67% over the past three months and nearly 29% for the month. This performance has been fueled by...